Ameritas Investment Company LLC bought a new position in shares of Invitae Co. (NYSE:NVTA) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 5,801 shares of the medical research company’s stock, valued at approximately $222,000.
A number of other institutional investors and hedge funds also recently modified their holdings of NVTA. Evoke Wealth LLC acquired a new position in Invitae during the first quarter worth about $26,000. Abundance Wealth Counselors acquired a new position in Invitae during the first quarter worth about $29,000. Orion Capital Management LLC acquired a new position in Invitae during the fourth quarter worth about $31,000. Baldwin Brothers Inc. MA acquired a new position in Invitae during the first quarter worth about $31,000. Finally, Wealthcare Advisory Partners LLC acquired a new position in Invitae during the first quarter worth about $32,000. Institutional investors own 90.30% of the company’s stock.
Shares of NVTA opened at $29.32 on Thursday. The company has a current ratio of 5.35, a quick ratio of 5.14 and a debt-to-equity ratio of 0.19. The firm’s 50 day moving average price is $30.34. Invitae Co. has a 1 year low of $25.24 and a 1 year high of $61.59.
Several analysts have recently commented on NVTA shares. The Goldman Sachs Group started coverage on shares of Invitae in a research report on Thursday, June 3rd. They issued a “neutral” rating and a $33.00 price target on the stock. Raymond James started coverage on shares of Invitae in a research report on Tuesday, June 15th. They issued an “outperform” rating and a $37.00 price target on the stock. Morgan Stanley lowered their price target on shares of Invitae from $45.00 to $41.00 and set an “equal weight” rating on the stock in a research report on Thursday, May 6th. Zacks Investment Research upgraded shares of Invitae from a “sell” rating to a “hold” rating in a research report on Thursday, July 8th. Finally, SVB Leerink lowered their price target on shares of Invitae from $65.00 to $50.00 and set an “outperform” rating on the stock in a research report on Wednesday, May 5th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $44.22.
In other Invitae news, insider Katherine Stueland sold 20,340 shares of the stock in a transaction that occurred on Monday, June 14th. The shares were sold at an average price of $31.60, for a total transaction of $642,744.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Sean E. George sold 3,675 shares of the stock in a transaction that occurred on Tuesday, June 22nd. The stock was sold at an average price of $33.02, for a total transaction of $121,348.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 97,351 shares of company stock worth $2,911,698. 2.90% of the stock is currently owned by insiders.
Invitae Company Profile
Invitae Corporation, a medical genetics company, integrates genetic information into healthcare decision-making by clinicians and patients in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases.
Recommended Story: What does it mean to hold a stock in street name?
Want to see what other hedge funds are holding NVTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invitae Co. (NYSE:NVTA).
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.